Fig. 4
From: Kinase-targeted cancer therapies: progress, challenges and future directions
Interruption of the BCR-Abl pathway can be achieved by Gleevec (imatinib mesylate)
Fig. 4 | Molecular Cancer
From: Kinase-targeted cancer therapies: progress, challenges and future directions
Interruption of the BCR-Abl pathway can be achieved by Gleevec (imatinib mesylate)
